ANI Pharmaceuticals(US:ANIP) Globenewswire·2025-12-01 11:50Core Points - Patrick D. Walsh will retire as Chairman of ANI Pharmaceuticals, effective after the 2026 Annual Meeting of Stockholders, having served the company with distinction [1][2] - Thomas J. Haughey has been unanimously elected as the new Chairman of the Board, having been a member since May 2018 [1][2] - Haughey will step down from his role as Chair of the Audit and Finance Committee, with Jeanne Thoma taking over that position [2] Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [3] - The company aims to deliver sustainable growth through its Rare Disease business, Generics business, and Brands business, targeting areas such as ophthalmology, rheumatology, nephrology, neurology, and pulmonology [3]